| Name | prostate specific antigen |
|---|---|
| Synonyms | NPSA; Prostate specific antigen; novel prostate specific antigen; Prostate specific antigens; novel prostate specific antigens |
| Name | valone |
|---|---|
| CAS |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 10873066 | Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, Padley DJ, Peshwa MV, Pitot HC, Richardson RL, Smits BJ, Sopapan P, Strang G, Valone FH, Vuk-Pavlovic S: Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res. 2000 Jun;6(6):2175-82. Circulating prostate-specific antigen levels dropped in three patients. |
1(0,0,0,1) | Details |
| 11777265 | Valone FH, Small E, MacKenzie M, Burch P, Lacy M, Peshwa MV, Laus R: Dendritic cell-based treatment of cancer: closing in on a cellular therapy. Cancer J. 2001 Nov-Dec;7 Suppl 2:S53-61. Provenge has demonstrated antitumor activity in hormone-refractory prostate cancer; approximately 20% of patients experienced decreased prostate-specific antigen (i.e., PSA) levels and a similar percentage experienced disease stabilization. |
1(0,0,0,1) | Details |
| 11099318 | Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH: Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000 Dec 1;18(23):3894-903. Three patients had a more than 50% decline in prostate-specific antigen (PSA) level, and another three patients had 25% to 49% decreases in PSA. |
1(0,0,0,1) | Details |